Management of perioperative systemic inflammation during cardiopulmonary bypass: We need a multimodal approach

Recent Patents on Cardiovascular Drug Discovery

Volumn 7, Issue 3, 2012, Pages 163-

  Faraoni, David ^a  

^a HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR; CORTICOSTEROID; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; KETAMINE; PLASMA PROTEIN; REGULATOR PROTEIN; STEROID;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING DISORDER; BLOOD CONSERVATION; CAPILLARY PERMEABILITY; CARDIOPULMONARY BYPASS; EDITORIAL; ENDOTOXEMIA; FIBRINOLYSIS; HEART SURGERY; HEMOLYSIS; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MEDIATOR RELEASE; MULTIPLE ORGAN FAILURE; PERIOPERATIVE PERIOD; PEROPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REPERFUSION INJURY; SHEAR STRESS; SYSTEMIC HOST REACTION; THROMBOCYTE DYSFUNCTION; THROMBOEMBOLISM; TREATMENT OUTCOME; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT; METHODOLOGY; MULTIMODALITY CANCER THERAPY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

CARDIOPULMONARY BYPASS; COMBINED MODALITY THERAPY; HUMANS; PERIOPERATIVE CARE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84870220766     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489012803832775     Document Type: Editorial

References (14)

1. Sniecinski RM, Chandler WL. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg 2011; 113: 1319-33.
2. Smith EE, Naftel DC, Blackstone EH, Kirklin JW. Microvascular permeability after cardiopulmonary bypass. An experimental study. J Thorac Cardiovasc Surg 1987; 94: 225-33.
3. Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, et al. The inflammatory response to cardiopulmonary bypass: Part 1--mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009; 23: 223-31.
4. van den Born BJ, Lowenberg EC, van der Hoeven NV, de Laat B, Meijers JC, Levi M, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens 2011; 29: 922-7.
5. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: S715-20.
6. Belhaj A. Actual knowledge about systemic inflammation reaction during cardiopulmonary bypass. Recent Pat Cardiovasc Drug Discov 2012.
7. Nebelsiek T, Beiras-Fernandez A, Kilger E, Möhnle P, Weis F. Routine use of corticosteroids to prevent inflammation response in cardiac surgery. Recent Pat Cardiovasc Drug Discov 2012.
8. Kilger E, Heyn J, Beiras-Fernandez A, Luchting B, Weis F. Stress doses of hydrocortisone reduce systemic inflammatory response in patients undergoing cardiac surgery without cardiopulmonary bypass. Minerva Anestesiologica 2011; 77: 268-74.
9. Cappabianca G, Rotunno C, de Luca Tupputi Schinosa L, Ranieri VM, Paparella D. Protective effects of steroids in cardiac surgery: a meta-analysis of randomized double-blind trials. J Cardiothorac Vasc Anesth 2011; 25: 156-165.
10. Dieleman JM, van Paassen J, van Dijk D, Arbous MS, Kalkman CJ, Vandenbroucke JP, et al. Prophylactic corticosteroids for cardiopulmonary bypass in adults. Cochrane Database Syst Rev 2011; 5: CD005566.
11. Van Aelbrouck C, Englberger L, Faraoni D. Review of the fibrinolytic system: Comparison of different antifibrinolytics used during cardiopulmonary bypass. Rec Pat Cardiovasc Drug Discov 2012.
12. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-31.
13. De Somer F. Advances in cardiopulmonary bypass technology and impacts on systemic host reaction after cardiac surgery. Rec Pat Cardiovasc Drug Discov 2012.
14. Royster RL, Grosshans DW, Kon ND. A multimodal approach to address the inflammation of cardiopulmonary bypass? J Cardiothorac Vasc Anesth 2011; 25: e35.